Amedisys, Inc. Logo

Amedisys, Inc.

AMED

(2.5)
Stock Price

97,21 USD

0.39% ROA

0.98% ROE

1153.67x PER

Market Cap.

3.055.782.212,00 USD

47.14% DER

0% Yield

0.46% NPM

Amedisys, Inc. Stock Analysis

Amedisys, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Amedisys, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (47%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

3 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (78.848) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

5 ROE

The stock's ROE falls within an average range (0.25%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (0.39%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

7 PBV

The stock's PBV ratio (2.93x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Amedisys, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Amedisys, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Amedisys, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Amedisys, Inc. Revenue
Year Revenue Growth
1993 14.000.000
1994 24.500.000 42.86%
1995 37.600.000 34.84%
1996 46.060.226 18.37%
1997 54.496.000 15.48%
1998 38.086.000 -43.09%
1999 97.411.000 60.9%
2000 90.755.000 -7.33%
2001 110.174.000 17.63%
2002 129.424.000 14.87%
2003 142.473.000 9.16%
2004 227.089.000 37.26%
2005 381.558.000 40.48%
2006 541.148.000 29.49%
2007 697.934.000 22.46%
2008 1.187.415.000 41.22%
2009 1.513.459.000 21.54%
2010 1.634.319.000 7.4%
2011 1.470.358.000 -11.15%
2012 1.487.905.000 1.18%
2013 1.249.344.000 -19.09%
2014 1.204.554.000 -3.72%
2015 1.280.541.000 5.93%
2016 1.437.454.000 10.92%
2017 1.533.680.000 6.27%
2018 1.662.578.000 7.75%
2019 1.955.633.000 14.99%
2020 2.071.519.000 5.59%
2021 2.214.112.000 6.44%
2022 2.223.199.000 0.41%
2023 2.224.948.000 0.08%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Amedisys, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Amedisys, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 4.700.000
1994 8.500.000 44.71%
1995 13.800.000 38.41%
1996 18.511.698 25.45%
1997 24.443.000 24.27%
1998 44.441.000 45%
1999 30.089.000 -47.7%
2000 49.251.000 38.91%
2001 53.665.000 8.23%
2002 63.060.000 14.9%
2003 69.581.000 9.37%
2004 97.633.000 28.73%
2005 168.424.000 42.03%
2006 229.928.000 26.75%
2007 278.889.000 17.56%
2008 423.277.000 34.11%
2009 509.756.000 16.96%
2010 566.546.000 10.02%
2011 341.482.000 -65.91%
2012 535.259.000 36.2%
2013 474.074.000 -12.91%
2014 441.738.000 -7.32%
2015 452.435.000 2.36%
2016 503.430.000 10.13%
2017 482.213.000 -4.4%
2018 501.306.000 3.81%
2019 607.926.000 17.54%
2020 668.300.000 9.03%
2021 711.240.000 6.04%
2022 754.058.000 5.68%
2023 771.928.000 2.31%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Amedisys, Inc. EBITDA
Year EBITDA Growth
1993 -200.000
1994 500.000 140%
1995 1.800.000 72.22%
1996 2.088.418 13.81%
1997 652.000 -220.31%
1998 -27.390.000 102.38%
1999 25.232.000 208.55%
2000 2.767.000 -811.89%
2001 10.612.000 73.93%
2002 19.943.000 46.79%
2003 16.919.000 -17.87%
2004 37.563.000 54.96%
2005 56.969.000 34.06%
2006 76.263.000 25.3%
2007 106.752.000 28.56%
2008 178.534.000 40.21%
2009 261.616.000 31.76%
2010 231.550.000 -12.98%
2011 -429.582.000 153.9%
2012 95.634.000 549.19%
2013 47.812.000 -100.02%
2014 60.607.000 21.11%
2015 107.779.000 43.77%
2016 90.840.000 -18.65%
2017 132.990.000 31.69%
2018 179.619.000 25.96%
2019 240.728.000 25.39%
2020 293.951.000 18.11%
2021 329.923.000 10.9%
2022 256.445.000 -28.65%
2023 261.868.000 2.07%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Amedisys, Inc. Gross Profit
Year Gross Profit Growth
1993 4.800.000
1994 9.000.000 46.67%
1995 15.800.000 43.04%
1996 19.655.440 19.62%
1997 23.855.000 17.6%
1998 15.163.000 -57.32%
1999 50.521.000 69.99%
2000 49.287.000 -2.5%
2001 61.128.000 19.37%
2002 71.180.000 14.12%
2003 83.919.000 15.18%
2004 131.011.000 35.95%
2005 218.526.000 40.05%
2006 305.690.000 28.51%
2007 389.200.000 21.46%
2008 624.782.000 37.71%
2009 788.994.000 20.81%
2010 813.859.000 3.06%
2011 688.010.000 -18.29%
2012 646.759.000 -6.38%
2013 531.348.000 -21.72%
2014 513.493.000 -3.48%
2015 554.626.000 7.42%
2016 604.399.000 8.24%
2017 632.954.000 4.51%
2018 669.715.000 5.49%
2019 805.296.000 16.84%
2020 886.150.000 9.12%
2021 980.756.000 9.65%
2022 962.774.000 -1.87%
2023 978.436.000 1.6%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Amedisys, Inc. Net Profit
Year Net Profit Growth
1993 -100.000
1994 0 0%
1995 900.000 100%
1996 18.321 -4812.4%
1997 -1.194.000 101.53%
1998 -24.871.000 95.2%
1999 1.300.000 2013.15%
2000 6.370.000 79.59%
2001 5.386.000 -18.27%
2002 752.000 -616.22%
2003 8.407.000 91.06%
2004 20.504.000 59%
2005 30.102.000 31.88%
2006 38.255.000 21.31%
2007 65.113.000 41.25%
2008 86.682.000 24.88%
2009 135.837.000 36.19%
2010 112.580.000 -20.66%
2011 -382.464.000 129.44%
2012 -83.588.000 -357.56%
2013 -96.178.000 13.09%
2014 12.776.000 852.8%
2015 -3.021.000 522.91%
2016 37.261.000 108.11%
2017 30.301.000 -22.97%
2018 119.346.000 74.61%
2019 126.833.000 5.9%
2020 183.608.000 30.92%
2021 209.072.000 12.18%
2022 118.609.000 -76.27%
2023 103.840.000 -14.22%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Amedisys, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 -6 100%
1999 0 0%
2000 1 0%
2001 1 0%
2002 0 0%
2003 1 0%
2004 1 100%
2005 1 0%
2006 2 0%
2007 3 50%
2008 3 33.33%
2009 5 25%
2010 4 0%
2011 -13 130.77%
2012 -3 -550%
2013 -3 33.33%
2014 0 0%
2015 0 0%
2016 1 100%
2017 1 0%
2018 4 100%
2019 4 0%
2020 6 40%
2021 6 16.67%
2022 4 -100%
2023 3 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Amedisys, Inc. Free Cashflow
Year Free Cashflow Growth
1993 -200.000
1994 -1.800.000 88.89%
1995 1.200.000 250%
1996 -3.900.260 130.77%
1997 -2.598.000 -50.13%
1998 4.305.000 160.35%
1999 -10.124.000 142.52%
2000 6.576.000 253.95%
2001 -5.762.000 214.13%
2002 9.852.000 158.49%
2003 19.999.000 50.74%
2004 24.480.000 18.3%
2005 23.147.000 -5.76%
2006 13.809.000 -67.62%
2007 64.452.000 78.57%
2008 117.626.000 45.21%
2009 206.086.000 42.92%
2010 139.926.000 -47.28%
2011 97.248.000 -43.89%
2012 21.232.000 -358.03%
2013 60.527.000 64.92%
2014 -77.542.000 178.06%
2015 86.356.000 189.79%
2016 46.542.000 -85.54%
2017 95.024.000 51.02%
2018 216.925.000 56.19%
2019 194.112.000 -11.75%
2020 283.620.000 31.56%
2021 182.172.000 -55.69%
2022 126.068.000 -44.5%
2023 -11.041.000 1241.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Amedisys, Inc. Operating Cashflow
Year Operating Cashflow Growth
1993 0
1994 -1.000.000 100%
1995 1.600.000 162.5%
1996 -934.841 271.15%
1997 -1.142.000 18.14%
1998 7.626.000 114.98%
1999 -9.177.000 183.1%
2000 6.914.000 232.73%
2001 7.662.000 9.76%
2002 11.119.000 31.09%
2003 21.788.000 48.97%
2004 29.711.000 26.67%
2005 43.540.000 31.76%
2006 43.080.000 -1.07%
2007 93.085.000 53.72%
2008 150.741.000 38.25%
2009 247.659.000 39.13%
2010 206.273.000 -20.06%
2011 141.663.000 -45.61%
2012 69.494.000 -103.85%
2013 102.263.000 32.04%
2014 -65.534.000 256.05%
2015 107.785.000 160.8%
2016 62.259.000 -73.12%
2017 105.731.000 41.12%
2018 223.483.000 52.69%
2019 202.000.000 -10.64%
2020 288.952.000 30.09%
2021 188.893.000 -52.97%
2022 133.283.000 -41.72%
2023 -9.843.000 1454.09%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Amedisys, Inc. Capital Expenditure
Year Capital Expenditure Growth
1993 200.000
1994 800.000 75%
1995 400.000 -100%
1996 2.965.419 86.51%
1997 1.456.000 -103.67%
1998 3.321.000 56.16%
1999 947.000 -250.69%
2000 338.000 -180.18%
2001 13.424.000 97.48%
2002 1.267.000 -959.51%
2003 1.789.000 29.18%
2004 5.231.000 65.8%
2005 20.393.000 74.35%
2006 29.271.000 30.33%
2007 28.633.000 -2.23%
2008 33.115.000 13.53%
2009 41.573.000 20.34%
2010 66.347.000 37.34%
2011 44.415.000 -49.38%
2012 48.262.000 7.97%
2013 41.736.000 -15.64%
2014 12.008.000 -247.57%
2015 21.429.000 43.96%
2016 15.717.000 -36.34%
2017 10.707.000 -46.79%
2018 6.558.000 -63.27%
2019 7.888.000 16.86%
2020 5.332.000 -47.94%
2021 6.721.000 20.67%
2022 7.215.000 6.85%
2023 1.198.000 -502.25%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Amedisys, Inc. Equity
Year Equity Growth
1993 1.900.000
1994 2.200.000 13.64%
1995 4.300.000 48.84%
1996 4.314.781 0.34%
1997 8.274.000 47.85%
1998 -11.684.000 170.81%
1999 -10.185.000 -14.72%
2000 -1.920.000 -430.47%
2001 3.309.000 158.02%
2002 16.963.000 80.49%
2003 51.399.000 67%
2004 148.473.000 65.38%
2005 192.599.000 22.91%
2006 364.007.000 47.09%
2007 446.971.000 18.56%
2008 561.335.000 20.37%
2009 735.166.000 23.65%
2010 877.857.000 16.25%
2011 518.868.000 -69.19%
2012 452.340.000 -14.71%
2013 372.201.000 -21.53%
2014 397.167.000 6.29%
2015 409.568.000 3.03%
2016 460.203.000 11%
2017 515.321.000 10.7%
2018 482.633.000 -6.77%
2019 641.513.000 24.77%
2020 810.741.000 20.87%
2021 976.323.000 16.96%
2022 1.106.573.000 11.77%
2023 1.093.518.000 -1.19%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Amedisys, Inc. Assets
Year Assets Growth
1993 4.300.000
1994 6.300.000 31.75%
1995 11.500.000 45.22%
1996 16.858.787 31.79%
1997 22.870.000 26.28%
1998 44.428.000 48.52%
1999 42.084.000 -5.57%
2000 41.570.000 -1.24%
2001 47.640.000 12.74%
2002 58.324.000 18.32%
2003 92.473.000 36.93%
2004 199.733.000 53.7%
2005 339.997.000 41.25%
2006 463.756.000 26.69%
2007 587.111.000 21.01%
2008 1.070.194.000 45.14%
2009 1.172.351.000 8.71%
2010 1.299.825.000 9.81%
2011 858.285.000 -51.44%
2012 730.595.000 -17.48%
2013 726.406.000 -0.58%
2014 669.742.000 -8.46%
2015 685.085.000 2.24%
2016 734.029.000 6.67%
2017 813.482.000 9.77%
2018 717.118.000 -13.44%
2019 1.262.745.000 43.21%
2020 1.567.198.000 19.43%
2021 1.856.968.000 15.6%
2022 1.976.245.000 6.04%
2023 2.027.417.000 2.52%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Amedisys, Inc. Liabilities
Year Liabilities Growth
1993 2.400.000
1994 4.100.000 41.46%
1995 7.200.000 43.06%
1996 12.355.737 41.73%
1997 14.590.000 15.31%
1998 56.009.000 73.95%
1999 52.188.000 -7.32%
2000 43.490.000 -20%
2001 44.266.000 1.75%
2002 41.361.000 -7.02%
2003 41.074.000 -0.7%
2004 51.260.000 19.87%
2005 147.398.000 65.22%
2006 99.749.000 -47.77%
2007 139.291.000 28.39%
2008 508.076.000 72.58%
2009 436.016.000 -16.53%
2010 420.110.000 -3.79%
2011 338.137.000 -24.24%
2012 276.362.000 -22.35%
2013 353.927.000 21.92%
2014 271.980.000 -30.13%
2015 274.649.000 0.97%
2016 272.887.000 -0.65%
2017 297.056.000 8.14%
2018 234.485.000 -26.68%
2019 621.232.000 62.25%
2020 756.457.000 17.88%
2021 880.645.000 14.1%
2022 869.672.000 -1.26%
2023 933.899.000 6.88%

Amedisys, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
68.28
Net Income per Share
0.08
Price to Earning Ratio
1153.67x
Price To Sales Ratio
1.37x
POCF Ratio
25.94
PFCF Ratio
29.07
Price to Book Ratio
2.94
EV to Sales
1.56
EV Over EBITDA
13.79
EV to Operating CashFlow
29.45
EV to FreeCashFlow
32.99
Earnings Yield
0
FreeCashFlow Yield
0.03
Market Cap
3,06 Bil.
Enterprise Value
3,47 Bil.
Graham Number
7.63
Graham NetNet
-18.33

Income Statement Metrics

Net Income per Share
0.08
Income Quality
74.06
ROE
0
Return On Assets
0.01
Return On Capital Employed
0.1
Net Income per EBT
0.26
EBT Per Ebit
0.25
Ebit per Revenue
0.07
Effective Tax Rate
0.76

Margins

Sales, General, & Administrative to Revenue
0.36
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.52
Operating Profit Margin
0.07
Pretax Profit Margin
0.02
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
5.69
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
3.61
Free CashFlow per Share
3.22
Capex to Operating CashFlow
-0.11
Capex to Revenue
-0.01
Capex to Depreciation
-0.21
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
52.36
Days Payables Outstanding
10.16
Days of Inventory on Hand
10.71
Receivables Turnover
6.97
Payables Turnover
35.92
Inventory Turnover
34.06
Capex per Share
-0.39

Balance Sheet

Cash per Share
2,39
Book Value per Share
31,88
Tangible Book Value per Share
-7.81
Shareholders Equity per Share
31.88
Interest Debt per Share
15.91
Debt to Equity
0.47
Debt to Assets
0.24
Net Debt to EBITDA
1.64
Current Ratio
1
Tangible Asset Value
-0,25 Bil.
Net Current Asset Value
-0,47 Bil.
Invested Capital
0.47
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.67
Average Receivables
0,30 Bil.
Average Payables
0,04 Bil.
Average Inventory
32998000
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Amedisys, Inc. Dividends
Year Dividends Growth

Amedisys, Inc. Profile

About Amedisys, Inc.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

CEO
Mr. Richard M. Ashworth
Employee
19.000
Address
3854 American Way
Baton Rouge, 70816

Amedisys, Inc. Executives & BODs

Amedisys, Inc. Executives & BODs
# Name Age
1 Mr. Scott G. Ginn
Executive Vice President, Chief Operating Officer, Chief Financial Officer & Principal Financial Officer
70
2 Mr. Pete Hartley
Chief Technology Officer & Senior Vice President of Business Operations Systems
70
3 Ms. Allyson Guidroz
Chief Accounting Officer & Principal Accounting Officer
70
4 Mr. Richard M. Ashworth
President, Chief Executive Officer & Director
70
5 Ms. Jennifer Guckert Griffin
Senior Vice President, Deputy General Counsel, Corporate Secretary & Interim Chief Legal Officer
70
6 Kendra Kimmons
Vice President of Marketing & Communications & Media Relations
70
7 Mr. Adam Holton
Chief People Officer
70
8 Mr. Michael P. North
Chief Information Officer
70
9 Ms. Denise Bohnert
Chief Compliance Officer
70
10 Mr. Nick Muscato
Chief Strategy Officer
70

Amedisys, Inc. Competitors